ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).

MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were presented at AHA in 2023 which showed that the MINT trial did not demonstrate a statistically significant recurrence in the rate of 30-day death or recurrent MI in patients with acute MI and anaemia assigned to a restrictive transfusion strategy as compared to a liberal strategy.

This subanalysis investigated the effects of restrictive transfusion strategy as compared to a liberal transfusion strategy in patients with type 1 and type 2 MI. Findings suggest that patients with type 1 MI and anaemia randomized to receive a restrictive transfusion strategy had higher relative and absolute rates of death and MI at 30 days compared to those receiving a liberal transfusion strategy. In patients with Type 2 MI, no differencial effect between restrictive versus liberal transfusion strategies was observed. The MINT trial was powered for the primary outcome analysis, however, therefore these inconclusive results require further study.
 

Interview Questions:

1. What is the importance of this study?
2. What was the design and patient cohort for this subgroup analysis?
3. What were your key findings?
4. How do these findings illuminate or change perspectives of the data released in 2023?
5. What are your take-home messages?
6. What further research is required?

For more content from ACC.24 head to the Late-breaking Science Video Collection.

Recorded on-site at ACC 2024, Atlanta.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editors: Jordan Rance, Mirjam Boros

Video Specialists: Dan Brent, Tom Green, Mike Knight